MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation
Yuanzhang Fang1, Lifei Wang1, Changlin Wan1
1Department of Medical and Molecular Genetics.
Abstract:
Immune evasion is a pivotal event in tumor progression. To eliminate human cancer cells, current immune checkpoint therapy is set to boost CD8+ T cell-mediated cytotoxicity. However, this action is eventually dependent on the efficient recognition of tumor-specific antigens via T cell receptors. One primary mechanism by which tumor cells evade immune surveillance is to downregulate their antigen presentation. Little progress has been made toward harnessing potential therapeutic targets for enhancing antigen presentation on the tumor cell. Here, we identified MAL2 as a key player that determines the turnover of the antigen-loaded MHC-I complex and reduces the antigen presentation on tumor cells. MAL2 promotes the endocytosis of tumor antigens via direct interaction with the MHC-I complex and endosome-associated RAB proteins. In preclinical models, depletion of MAL2 in breast tumor cells profoundly enhanced the cytotoxicity of tumor-infiltrating CD8+ T cells and suppressed breast tumor growth, suggesting that MAL2 is a potential therapeutic target for breast cancer immunotherapy.
Insights
Researchers identified MAL2 as a target to enhance cancer cell antigen presentation. Depleting MAL2 boosts T cell attacks on breast tumors, suggesting its therapeutic potential in cancer immunotherapy.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Tumor immune evasion is a major obstacle in cancer progression.
- Current immunotherapies aim to enhance CD8+ T cell responses against cancer cells.
- Efficient antigen presentation by tumor cells is crucial for T cell recognition and effective anti-tumor immunity.
Purpose of the Study:
- To identify novel therapeutic targets for enhancing tumor antigen presentation.
- To investigate the role of MAL2 in regulating antigen presentation on tumor cells.
- To evaluate MAL2 as a potential target for breast cancer immunotherapy.
Main Methods:
- Investigated the mechanism by which tumor cells downregulate antigen presentation.
- Identified MAL2 as a key protein involved in MHC-I complex turnover.
- Utilized preclinical breast tumor models to assess the impact of MAL2 depletion on anti-tumor immunity.
Main Results:
- MAL2 was found to promote the endocytosis of tumor antigens by interacting with MHC-I and RAB proteins.
- Depletion of MAL2 in breast tumor cells significantly enhanced CD8+ T cell-mediated cytotoxicity.
- Suppression of breast tumor growth was observed in preclinical models following MAL2 depletion.
Conclusions:
- MAL2 plays a critical role in reducing antigen presentation on tumor cells by regulating MHC-I complex turnover.
- Targeting MAL2 represents a promising strategy to enhance anti-tumor immunity and overcome immune evasion in breast cancer.
- MAL2 is a potential therapeutic target for improving the efficacy of breast cancer immunotherapy.
More Related Videos
Related Concept Videos
02:23Abnormal Proliferation
01:27Tumor Immunotherapy
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:17The Tumor Microenvironment
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...